Terms & Conditions

Except for the historical information contained in this website, the matters set forth herein, including statements regarding Sequenom’s Fetal Nucleic Acid Technology and its potential, including potential as an alternative to amniocentesis, the impact or significance of the Technology, the first application of the Technology to be offered, the potential application of the Technology to a number of genetic defects, and the ability to determine the condition of a fetus and to treat or prevent a majority of birth defects before a child is born, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the efforts of other parties, new technology development, product development and commercialization, competition, government regulation, obtaining or maintaining regulatory approvals, market acceptance of new technology such as Sequenom’s Fetal Nucleic Acid Technology, and other risks detailed from time to time in Sequenom’s SEC filings, including Sequenom’s Annual Report on Form 10-K for the year ended December 31, 2005, Sequenom’s most recently filed quarterly report on Form 10-Q, and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission (SEC). These forward-looking statements are based on current information that is likely to change. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.